Mycobacteriology Unit, Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Internal Medicine Department, UZ Brussel, Brussels, Belgium.
Sci Rep. 2023 Jun 27;13(1):10444. doi: 10.1038/s41598-023-36955-y.
Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target gene, atpE, are rare in clinical isolates, mutations in the Rv0678 gene, a transcriptional repressor regulating the efflux pump MmpS5-MmpL5, are increasingly observed, and have been linked to worse treatment outcomes. Nevertheless, underlying mechanisms of (cross)-resistance remain incompletely resolved. Our study aims to distinguish resistance associated variants from other polymorphisms, by assessing the in vitro onset of mutations under drug pressure, combined with their impact on minimum inhibitory concentrations (MICs) and on protein stability. For this purpose, isolates were exposed in vitro to sub-lethal concentrations of BDQ or clofazimine (CFZ). Selected colonies had BDQ- and CFZ-MICs determined on 7H10 and 7H11 agar. Sanger sequencing and additional Deeplex Myc-TB and whole genome sequencing (WGS) for a subset of isolates were used to search for mutations in Rv0678, atpE and pepQ. In silico characterization of relevant mutations was performed using computational tools. We found that colonies that grew on BDQ medium had mutations in Rv0678, atpE or pepQ, while CFZ-exposed isolates presented mutations in Rv0678 and pepQ, but none in atpE. Twenty-eight Rv0678 mutations had previously been described among in vitro selected mutants or in patients' isolates, while 85 were new. Mutations were scattered across the Rv0678 gene without apparent hotspot. While most Rv0678 mutations led to an increased BDQ- and/or CFZ-MIC, only a part of them surpassed the critical concentration (69.1% for BDQ and 87.9% for CFZ). Among the mutations leading to elevated MICs for BDQ and CFZ, we report a synonymous Val1Val mutation in the Rv0678 start codon. Finally, in silico characterization of Rv0678 mutations suggests that especially the C46R mutant may render Rv0678 less stable.
耐多药结核病是一个严重的全球健康威胁。贝达喹啉(BDQ)是一种相对较新的核心药物,针对分枝杆菌(Mtb)的呼吸链。虽然 BDQ 靶基因 atpE 的突变在临床分离株中很少见,但 Rv0678 基因的突变,一种调节外排泵 MmpS5-MmpL5 的转录抑制剂,越来越常见,并与更差的治疗结果相关。然而,(交叉)耐药的潜在机制仍未完全解决。我们的研究旨在通过评估药物压力下突变的体外发生情况,并结合其对最小抑菌浓度(MICs)和蛋白质稳定性的影响,将耐药相关变异与其他多态性区分开来。为此,将分离株在体外暴露于亚致死浓度的 BDQ 或氯法齐明(CFZ)下。选择的菌落通过 7H10 和 7H11 琼脂测定 BDQ 和 CFZ 的 MIC。对部分分离株进行 Sanger 测序和额外的 Deeplex Myc-TB 和全基因组测序(WGS),以搜索 Rv0678、atpE 和 pepQ 中的突变。使用计算工具对相关突变进行了计算机模拟特征描述。我们发现,在 BDQ 培养基上生长的菌落存在 Rv0678、atpE 或 pepQ 突变,而暴露于 CFZ 的分离株存在 Rv0678 和 pepQ 突变,但不存在 atpE 突变。28 种 Rv0678 突变先前在体外选择的突变体或患者分离株中已有描述,而 85 种为新突变。突变分散在 Rv0678 基因中,没有明显的热点。虽然大多数 Rv0678 突变导致 BDQ 和/或 CFZ-MIC 升高,但只有一部分超过了临界浓度(BDQ 为 69.1%,CFZ 为 87.9%)。在导致 BDQ 和 CFZ MIC 升高的突变中,我们报告了 Rv0678 起始密码子中的同义 Val1Val 突变。最后,对 Rv0678 突变的计算机模拟特征描述表明,特别是 C46R 突变可能使 Rv0678 变得不稳定。